HB4034 - 104th General Assembly
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| 1 | AN ACT concerning public aid. | |||||||||||||||||||
| 2 | Be it enacted by the People of the State of Illinois, | |||||||||||||||||||
| 3 | represented in the General Assembly: | |||||||||||||||||||
| 4 | Section 5. The Illinois Public Aid Code is amended by | |||||||||||||||||||
| 5 | changing Section 5-5.12f as follows: | |||||||||||||||||||
| 6 | (305 ILCS 5/5-5.12f) | |||||||||||||||||||
| 7 | Sec. 5-5.12f. Prescription drugs for mental illness; no | |||||||||||||||||||
| 8 | utilization or prior approval mandates. | |||||||||||||||||||
| 9 | (a) Notwithstanding any other provision of this Code to | |||||||||||||||||||
| 10 | the contrary, except as otherwise provided in subsection (b), | |||||||||||||||||||
| 11 | for the purpose of removing barriers to the timely treatment | |||||||||||||||||||
| 12 | of serious mental illnesses, prior authorization mandates and | |||||||||||||||||||
| 13 | utilization management controls shall not be imposed under the | |||||||||||||||||||
| 14 | fee-for-service and managed care medical assistance programs | |||||||||||||||||||
| 15 | on any FDA-approved prescription drug that is recognized by a | |||||||||||||||||||
| 16 | generally accepted standard medical reference as effective in | |||||||||||||||||||
| 17 | the treatment of conditions specified in the most recent | |||||||||||||||||||
| 18 | Diagnostic and Statistical Manual of Mental Disorders | |||||||||||||||||||
| 19 | published by the American Psychiatric Association if a | |||||||||||||||||||
| 20 | preferred or non-preferred drug is prescribed to an adult | |||||||||||||||||||
| 21 | patient to treat serious mental illness and (i) during the | |||||||||||||||||||
| 22 | preceding 60 days, the patient who experienced an inadequate | |||||||||||||||||||
| 23 | response was prescribed and unsuccessfully treated with a | |||||||||||||||||||
| |||||||
| |||||||
| 1 | 14-day treatment trial of a drug for the same clinical | ||||||
| 2 | condition that is included on the preferred drug list and (ii) | ||||||
| 3 | one of the following applies: | ||||||
| 4 | (1) the patient has changed providers, including, but | ||||||
| 5 | not limited to, a change from an inpatient to an | ||||||
| 6 | outpatient provider, and is stable on the drug that has | ||||||
| 7 | been previously prescribed, and received prior | ||||||
| 8 | authorization, if required; | ||||||
| 9 | (2) the patient has changed insurance coverage and is | ||||||
| 10 | stable on the drug that has been previously prescribed and | ||||||
| 11 | received prior authorization under the previous source of | ||||||
| 12 | coverage; or | ||||||
| 13 | (3) subject to federal law on maximum dosage limits | ||||||
| 14 | and safety edits adopted by the Department's Drug and | ||||||
| 15 | Therapeutics Board, including those safety edits and | ||||||
| 16 | limits needed to comply with federal requirements | ||||||
| 17 | contained in 42 CFR 456.703, the patient has previously | ||||||
| 18 | been prescribed and obtained prior authorization for the | ||||||
| 19 | drug and the prescription modifies the dosage, dosage | ||||||
| 20 | frequency, or both, of the drug as part of the same | ||||||
| 21 | treatment for which the drug was previously prescribed. | ||||||
| 22 | (b) The following safety edits shall be permitted for | ||||||
| 23 | prescription drugs covered under this Section: | ||||||
| 24 | (1) clinically appropriate drug utilization review | ||||||
| 25 | (DUR) edits, including, but not limited to, drug-to-drug, | ||||||
| 26 | drug-age, and drug-dose; | ||||||
| |||||||
| |||||||
| 1 | (2) generic drug substitution if a generic drug is | ||||||
| 2 | available for the prescribed medication in the same dosage | ||||||
| 3 | and formulation; and | ||||||
| 4 | (3) any utilization management control that is | ||||||
| 5 | necessary for the Department to comply with any current | ||||||
| 6 | consent decrees or federal waivers. | ||||||
| 7 | (c) As used in this Section, "serious mental illness" | ||||||
| 8 | means any one or more of the following diagnoses and | ||||||
| 9 | International Classification of Diseases, Tenth Revision, | ||||||
| 10 | Clinical Modification (ICD-10-CM) codes listed by the | ||||||
| 11 | Department of Human Services' Division of Mental Health, as | ||||||
| 12 | amended, on its official website: | ||||||
| 13 | (1) Delusional Disorder (F22) | ||||||
| 14 | (2) Brief Psychotic Disorder (F23) | ||||||
| 15 | (3) Schizophreniform Disorder (F20.81) | ||||||
| 16 | (4) Schizophrenia (F20.9) | ||||||
| 17 | (5) Schizoaffective Disorder (F25.x) | ||||||
| 18 | (6) Catatonia Associated with Another Mental Disorder | ||||||
| 19 | (Catatonia Specifier) (F06.1) | ||||||
| 20 | (7) Other Specified Schizophrenia Spectrum and Other | ||||||
| 21 | Psychotic Disorder (F28) | ||||||
| 22 | (8) Unspecified Schizophrenia Spectrum and Other | ||||||
| 23 | Psychotic Disorder (F29) | ||||||
| 24 | (9) Bipolar I Disorder (F31.xx) | ||||||
| 25 | (10) Bipolar II Disorder (F31.81) | ||||||
| 26 | (11) Cyclothymic Disorder (F34.0) | ||||||
| |||||||
| |||||||
| 1 | (12) Unspecified Bipolar and Related Disorder (F31.9) | ||||||
| 2 | (13) Disruptive Mood Dysregulation Disorder (F34.8) | ||||||
| 3 | (14) Major Depressive Disorder Single episode (F32.xx) | ||||||
| 4 | (15) Major Depressive Disorder, Recurrent episode | ||||||
| 5 | (F33.xx) | ||||||
| 6 | (16) Obsessive-Compulsive Disorder (F42) | ||||||
| 7 | (17) Posttraumatic Stress Disorder (F43.10) | ||||||
| 8 | (18) Anorexia Nervosa (F50.0x) | ||||||
| 9 | (19) Bulimia Nervosa (F50.2) | ||||||
| 10 | (20) Postpartum Depression (F53.0) | ||||||
| 11 | (21) Puerperal Psychosis (F53.1) | ||||||
| 12 | (22) Factitious Disorder Imposed on Another (F68.A) | ||||||
| 13 | (d) Notwithstanding any other provision of law, nothing in | ||||||
| 14 | this Section shall not be construed to conflict with Section | ||||||
| 15 | 1927(a)(1) and (b)(1)(A) of the federal Social Security Act | ||||||
| 16 | and any implementing regulations and agreements. | ||||||
| 17 | (Source: P.A. 103-593, eff. 6-7-24.) | ||||||
